Proof of Usefulness Report

Sorintellis

Analysis completed on 2/3/2026

+24
Proof of Usefulness Score
You're In Business

The project addresses a sophisticated problem in pharmaceutical portfolio management (PPM) with a theoretically sound AI solution. However, the submission is severely compromised by non-credible claims in critical metric fields. Specifically, the traction claim ('most people have used my product') is demonstrably false for a niche B2B tool, and the audience reach ('everyone') indicates a lack of market understanding or a low-quality submission. While the market timing for AI in pharma is favorable, the lack of verifiable data and the presence of 'garbage' inputs result in a minimal score.

Ready to Compete for $150k+ in Prizes?

Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes

View All Reports

Score Breakdown

Real World Utility+52.0
Audience Reach Impact+2.5
Technical Innovation+32.0
Evidence Of Traction+0.0
Market Timing Relevance+75.0
Functional Completeness+5.0
Subtotal+26.05
Usefulness Multiplierx0.92
Final Score+24

Project Details

Project URL
sorintellisgroup.com
Description
Sorintellis is a Montreal-based company revolutionizing pharmaceutical portfolio management (PPM) through a cutting-edge artificial intelligence-powered decision support system. We strongly believe that the traditionally known challenges, inherently associated with the process of drug development and its consequent development costs, go beyond the efficacy and innocuity of the pharmaceutical product. We develop the use of explainable machine learning for in-depth understanding of drug development risk network (DDRN) mapping to support decision-making processes for pharmaceutical portfolio management. We are on a mission to provide the pharmaceutical industry, contract research organizations (CROs), and life sciences mezzanine investment funds with an artificial intelligence (AI)-powered guidance tool for the due diligence and strategic scenario assessment of pharmaceutical portfolio management based on an a priori multidimensional risk estimation of a drug. Our DDRNAi technology aims to unlock critical insights to streamline drug clinical development. Our ML-driven system will add incremental value to guide Go/No Go decisions for important stakeholders in the pharmaceutical industry including CROs, pharmaceutical companies, and life-science venture capital investors. Join us in the innovative journey of reshaping the future of drug development and reimagining what is possible for an efficient pharmaceutical portfolio management: https://sorintellisgroup.com/contact-us/

Algorithm Insights

Market Position
Growing utility with room for optimization
User Engagement
Documented reach suggests active user community
Technical Stack
Modern tech stack aligned with sponsor technologies

Recommendations to Increase Usefulness Score

Document User Growth

Provide specific metrics on user acquisition and retention rates

Showcase Revenue Model

Detail sustainable monetization strategy and current revenue streams

Expand Evidence Base

Include testimonials, case studies, and third-party validation

Technical Roadmap

Share development milestones and feature completion timeline